MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthrit… Read more
MEDIPOST Co. Ltd - Asset Resilience Ratio
MEDIPOST Co. Ltd (078160) has an Asset Resilience Ratio of 0.72% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how MEDIPOST Co. Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down MEDIPOST Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩2.70 Billion | 0.72% |
| Total Liquid Assets | ₩2.70 Billion | 0.72% |
Asset Resilience Insights
- Limited Liquidity: MEDIPOST Co. Ltd maintains only 0.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
MEDIPOST Co. Ltd Industry Peers by Asset Resilience Ratio
Compare MEDIPOST Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
Biotoxtech Co. Ltd
KQ:086040 |
Biotechnology & Medical Research | 7.17% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 57.41% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
|
Pluristem
TA:PSTI |
Biotechnology & Medical Research | 48.26% |
Annual Asset Resilience Ratio for MEDIPOST Co. Ltd (2011–2024)
The table below shows the annual Asset Resilience Ratio data for MEDIPOST Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 14.61% | ₩60.53 Billion | ₩414.29 Billion | -12.54pp |
| 2023-12-31 | 27.15% | ₩122.03 Billion | ₩449.39 Billion | -3.60pp |
| 2022-12-31 | 30.76% | ₩122.34 Billion | ₩397.79 Billion | +8.59pp |
| 2021-12-31 | 22.16% | ₩56.32 Billion | ₩254.09 Billion | -3.56pp |
| 2020-12-31 | 25.72% | ₩56.54 Billion | ₩219.81 Billion | +18.13pp |
| 2019-12-31 | 7.59% | ₩16.23 Billion | ₩213.72 Billion | +0.61pp |
| 2018-12-31 | 6.99% | ₩12.28 Billion | ₩175.75 Billion | -7.97pp |
| 2017-12-31 | 14.96% | ₩21.63 Billion | ₩144.65 Billion | +0.91pp |
| 2016-12-31 | 14.04% | ₩25.17 Billion | ₩179.26 Billion | +10.56pp |
| 2015-12-31 | 3.48% | ₩6.37 Billion | ₩182.93 Billion | -1.78pp |
| 2014-12-31 | 5.26% | ₩9.78 Billion | ₩185.97 Billion | -6.29pp |
| 2013-12-31 | 11.54% | ₩16.83 Billion | ₩145.77 Billion | -16.68pp |
| 2012-12-31 | 28.22% | ₩38.79 Billion | ₩137.44 Billion | -7.00pp |
| 2011-12-31 | 35.22% | ₩46.42 Billion | ₩131.79 Billion | -- |